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Abstract
Background Studies have shown a familial predisposition
for anterior cruciate ligament (ACL) rupture and have been
followed by genetic-association studies on polymorphisms
in candidate genes in recent years. To date, no systematic
review with a best-evidence synthesis has evaluated the
influence of genetics on this devastating knee injury.
Objective Our objective was to evaluate the association
between genetic variants and ACL rupture.
Methods We performed an extensive search in Embase,
MEDLINE, Web of Science, Scopus, PubMed Publisher,
Cochrane Register of Clinical Trials, and Google scholar
up to 24 August 2015. Studies were eligible if they met the
following inclusion criteria: (1) design was a case–control
study, retrospective or prospective follow-up study, or a
randomized controlled trial (RCT); (2) the study examined
the association between a genetic variant and ACL rupture
in both an ACL and a control group. We determined the
risk of bias for all included studies.
Results We included a total of 16 studies (eight at high risk
of bias and eight with an unclear risk) that examined 33
different DNA variants. Conflicting evidence was found for
the COL1A1 rs1800012 and COL3A1 rs1800255 variants,
whereas limited evidence was found for no association of
the COL5A1 rs12722 and rs13946 and COL12A1 rs970547
variants (all encoding collagen). Evidence was insufficient
to draw conclusions as to whether any other genetic variant
identified in this review had any association with ACL
rupture.
Conclusions More research is needed to support a clear
association between ACL rupture and genetic variants.
Genome-wide studies are recommended for exploring more
potential genetic variants. Moreover, large prospective
studies are needed to draw robust conclusions.
Key Points
Anterior cruciate ligament (ACL) rupture is a very
common and severe knee injury that predominantly
occurs while participating in sports. It incurs high
costs and has disastrous clinical consequences.
Studies in recent years have suggested that genetic
predisposition is an important factor in its etiology.
This is the first systematic review with a best-
evidence synthesis regarding associations between
genetic variants and ACL rupture. We found some
potential genetic variants that require further
investigation, especially since we identified large
heterogeneity in the broad genetic variants studied
and outcome definitions.
More research with large samples, phenotype
homogeneity, and less bias is needed for a better
understanding of the etiology of ACL rupture. This
would allow us to take appropriate measures to
screen for and prevent this injury and its clinical
consequences.
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1 Introduction
An anterior cruciate ligament (ACL) rupture is a very
common and severe knee injury that predominantly occurs
during sports participation, primarily via a non-contact
mechanism [1, 2]. An ACL rupture is often accompanied
by meniscal tears (approximately 50%), medial collateral
ligament injuries (22%), and chondral lesions (16–46%)
and results in a tenfold increased risk of knee osteoarthritis
[3–6]. As a result, an ACL rupture is referred to as ‘the
stroke of the knee’ or ‘an old knee in a young patient’ [7].
ACL rupture reconstruction is one of the most commonly
performed orthopedic procedures, with an increasing inci-
dence across the globe: England (13.5 per 100,000 person-
years), Scandinavian countries (32–38 per 100,000 person-
years), Australia (52.0 per 100,000 person-years), and USA
(43.5 per 100,000 person-years) [8–13]. In absolute num-
bers, this means between 100,000 and 200,000 ACL rup-
tures are reconstructed annually in the USA alone [13, 14].
The high incidence, high costs, and disastrous clinical
consequences of ACL rupture mean it is important to be
aware of the cause and mechanism behind this injury. A
better understanding regarding the risk factors, etiology,
and mechanism is an important step in screening for and
preventing ACL rupture.
ACL rupture risk is determined by intrinsic and extrinsic
factors. Extrinsic factors include the intensity of the
physical activity and the type of playing surface [15–17].
Intrinsic factors include differences in anatomy, sex, neu-
romuscular control, and hormonal constitution [18–20]. For
example, the incidence of ACL rupture is 3–6 times higher
in women than in men [15, 21], which could be partially
explained by the smaller intercondylar notch, higher
estrogen concentration, and a movement pattern with an
increased hip adductor moment and knee valgus found in
women [18, 20]. Previous studies have indicated a familial
predisposition for ACL rupture. An individual with an
ACL rupture was twice as likely to have a relative with an
ACL rupture [22]. Hewett et al. [23] pointed out that twins
with an ACL rupture shared the same multiple risk factors.
This might be explained by an active lifestyle, since ath-
letes tend to injure their ACL more often than non-athletes
do. However, genetics or other intrinsic variations could
also be of influence.
A number of studies have suggested associations
between ACL rupture and various genetic variants, possi-
bly suggesting that genetic predisposition is a factor of
importance in ACL rupture. John et al. [24] recently pub-
lished a systematic review on a topic similar to ours, albeit
with some notable methodological differences between the
two reviews. In an attempt to conduct more sensitive
research, we searched more databases. We also used a
different risk-of-bias assessment tool and a best-evidence
approach to synthesizing the data, which allowed us to
weigh results for potential risk of bias and to grade evidence.
We believe these methodological differences enabled us to
generate more accurate conclusions.
To date, no systematic review with a best-evidence
synthesis has been performed concerning genetics and
ACL rupture. The objective of this systematic review was
to summarize the current evidence for an association
between genetic variants and ACL rupture.
2 Methods and Materials
2.1 Protocol
The reporting in this systematic review was conducted
according to the PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) statement [25].
2.2 Eligibility Criteria
Studies were included in the systematic review if they met
the following inclusion criteria: (1) design was a case–
control, retrospective or prospective follow-up study, or a
randomized controlled trial; (2) the study examined the
association between a genetic variant and an ACL rupture
in both an ACL and a control group; (3) the study was
written in English, Dutch, German, French, Spanish,
Turkish, or Swedish. We excluded studies for which no full
text was available, animal studies, and reviews.
2.3 Information Sources and Search
We conducted a systematic search of the following data-
bases up to 24 August 2015: Embase, MEDLINE, Web of
Science, Scopus, PubMed Publisher, Cochrane Register of
Clinical Trials, and Google scholar. The following search
strategy was used in Embase: (‘anterior cruciate ligament’/
de OR ‘anterior cruciate ligament injury’/de OR ‘anterior
cruciate ligament rupture’/de OR (‘knee injury’/de AND
(‘sports and sport related phenomena’/exp OR ‘ligament
injury’/exp)) OR (‘sport injury’/de AND (knee/exp OR
‘knee ligament’/exp OR ‘ligament injury’/exp)) OR (‘an-
terior cruciate’ OR acl OR ((ligament*) NEAR/6 (injur*
OR rupture* OR trauma* OR tear*))):ab,ti) AND (genet-
ics/exp OR ‘genetic parameters’/exp OR (genetic* OR
genom* OR gene OR genes OR (famil* NEAR/3 predis-
pos*)):ab,ti) NOT ([animals]/lim NOT [humans]/lim). This
search strategy was transferred into similar search strate-
gies in the databases described above. References in
reviews and full-text articles were screened to retrieve
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more studies that could be eligible for this systematic
review.
2.4 Study Selection
The results of the seven different search strategies were
combined and duplicates removed using EndNoteX5.
Three authors screened the results of these database sear-
ches independently by title and abstract. The final selection
for inclusion of the remaining full-text articles was made
by the same independent authors. Discrepancies were
resolved by consensus.
2.5 Data-Collection Process
One author extracted the general information, study design,
sample size, gene, corresponding variant, and product of
each study.
2.6 Risk-of-Bias Assessment
Three reviewers, independent of each other, assessed the
risk of bias of the studies using the Cochrane Centre
‘case–control tool’ [26]. Any disagreements were
resolved by consensus. This risk-of-bias tool included six
questions, four of which addressed bias (see Table 1).
Selection bias scoring was based on the source of
recruiting for cases and controls. Ideally, cases were
compared with population-based controls. Confounding
was scored based on age and sex. Ideally, both groups
were matched or adjusted for age and sex. In addition, the
studies included were scored for information bias. Ideally,
the methods used to extract DNA and to genotype the
genetic variant were the same. The risk of bias was
divided into three ranks: low, high, and unclear risk of
bias. A study was labelled ‘high risk’ if at least one bias
question was answered with ‘no’ and ‘low risk’ of bias
when all other questions were answered with ‘yes’. A
study was labelled ‘unclear risk’ of bias if all questions
were answered ‘doubtful’ or a mix of ‘doubtful’ and ‘yes’.
2.7 Summary Measures
An overview with odds ratios (ORs) was given of various
genetic variants and their associations with ACL rupture.
The ACL group consisted of individuals who experienced
an ACL rupture. The control group consisted of controls
with no history of ACL rupture. When possible, the asso-
ciation with ACL rupture was examined, with subgroups
being stratified according to sex and non-contact versus
contact mechanism, since these factors are known to
influence the risk of an ACL rupture.
2.8 Synthesis of Results
We refrained from statistically pooling the data because of
the different genetic variants and the heterogeneity of the
risk of bias between studies, providing a narrative summary
of the results as an alternative. Therefore, we performed a
‘best-evidence’ synthesis based on the study of van Tulder
et al. [27]. Evidence was defined as generally consistent if
C75% of the studies/cohorts reported consistent findings.
Strong evidence was defined as two or more studies with a
low risk of bias and generally consistent findings in all
studies/cohorts. Moderate evidence was defined as one
study with low risk of bias and two or more studies/cohorts
with a high risk of bias and generally consistent findings.
Limited evidence was defined as generally consistent
findings in one study with a low risk of bias or two or more
studies with a high risk of bias. Insufficient evidence was
defined as a finding in one study with a high risk of bias.
Conflicting evidence was defined as\75% of the studies
reporting consistent findings.
3 Results
3.1 Study Selection
Combining the search results of all databases retrieved a
total of 2559 studies. After removing duplicates, 1433
Table 1 List of questions used to assess risk of bias
# Criterion Question
1 Case Are the cases defined clearly and adequately?
2 Control Are the controls defined clearly and adequately?
3 Selection bias Is selection bias excluded sufficiently?
4 Defined exposure Is the exposure defined clearly, and is the method used to assess this exposure appropriate?
5 Determination Was blinding to exposure status maintained before determination of disease?
6 Confounding Are the main confounders identified and taken into account adequately for the design and analysis?
Information bias comprises questions 4 and 5
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studies remained. A further 1412 studies were excluded
after screening title and abstract. Five studies were exclu-
ded after accessing the full text: two because they did not
examine the association between genetic variants and ACL
ruptures and three because they lacked full text. Ultimately,
16 articles fell within the scope of this systematic review.
A flowchart of this process is shown in Fig. 1.
3.2 Study Characteristics
A summary of the 16 included studies is shown in Table 2;
all were case–control studies. Ten examined genetic vari-
ants in or near genes encoding collagens (collagen type I,
alpha 1 [COL1A1]; collagen type III, alpha 1 [COL3A1];
collagen type V, alpha 1 [COL5A1]; collagen type VI,
alpha 1 [COL6A1]; collagen type XII, alpha 1 [COL12A1]),
one study examined proteoglycans (aggrecan [ACAN],
biglycan [BCN], decorin [DCN], fibromodulin [FMOD],
lumican [LUM]), two examined matrix metalloproteinases
(matrix metalloproteinase 1 [MMP1], matrix metallopro-
teinase 3 [MMP3], matrix metalloproteinase 10 [MMP10],
matrix metalloproteinase 12 [MMP12]), one study exam-
ined a variant near growth-differentiation factor (growth
differentiation factor 5 [GDF5]), one investigated variants
in genes involved in the angiogenesis-associated signaling
cascade (vascular endothelial growth factor A [VEGFA],
kinase insert domain receptor [KDR], nerve growth factor
beta [NGFB], hypoxia-inducible factor 1-alpha [HIF1A]),
and, finally, one study focused on elastin (ELN) and fib-
rillin (fibrillin 2 [FBN2]). A total of 33 different genetic
variants were examined. O’Connell et al. [34] examined
two different case–control cohorts in one study: South
African and Polish. O’Connell et al. [34] and Ficek et al.
[29] examined the COL12A1 gene in the same population;
however, O’Connell et al. [34] only performed stratified
analyses, and Ficek et al. [29] analysed only the overall
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Fig. 1 PRISMA flowchart showing the study-selection process [25]. ACL anterior cruciate ligament
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Table 2 Study characteristics of the included studies
Study Design Patients with ACL
rupture (n)
Controls
(n)
Gene Product Variant
Ficek et al. [28] 2013 Case–
control
91 143 COL1A1 Collagen rs1800012
rs1107946
Ficek et al. [29] 2014 Case–
control
91 143 COL12A1 Collagen rs970547
Khoschnau et al. [30] 2008 Case–
control
233 325 COL1A1 Collagen rs1800012
Khoury et al. [31] 2015 Case–
control
141 219 ELN Elastin rs2071307
FBN2 Fibrillin rs331079
Malila et al. [32] 2011 Case–
control
86 100 MMP3 Matrix metalloproteinase –1612
Mannion et al. [33] 2014 Case–
control
227 234 ACAN Proteoglycans rs2351491
rs1042631
rs1516797
BGN rs1126499
rs1042103
DCN rs13312816
rs516115
FMOD rs7543148
rs10800912
LUM rs2268578
O’Connell et al. [34]a 2015 Case–
control
242b 235b COL3A1 Collagen rs1800255
91c 91c COL6A1 rs35796750
Posthumus et al. [35] 2009 Case–
control
117 130 COL1A1 Collagen rs1800012
Posthumus et al. [36] 2009 Case–
control
129 216 COL5A1 Collagen rs13946
rs12722
Posthumus et al. [37] 2010 Case–
control
129 216 COL12A1 Collagen rs240736
rs970547
Posthumus et al. [38] 2012 Case–
control
129 216 MMP1 Matrix metalloproteinase rs1799750
MMP3 rs679620
MMP10 rs486055
MMP12 rs2276109
Rahim et al. [39] 2014 Case–
control
227 227 VEGFA Angiogenesis-associated signaling
cascade genes
rs699947
rs1570360
rs2010963
KDR rs1870377
rs2071559
NGFB rs6678788
HIF1A rs11549465
Raleigh et al. [40] 2013 Case–
control
126 216 GDF5 Growth differentiation factor rs143383
Ste˛pien´-Słodkowska et al.
[41] 2013
Case–
control
138 183 COL1A1 Collagen rs1800012
Ste˛pien´-Słodkowska et al.
[42] 2015
Case–
control
138 183 COL3A1 Collagen rs1800255
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results. Therefore, these two studies were considered
independent of each other.
3.3 Risk of Bias
An overview of the risk of bias is shown in Table 3. Eight
studies were considered unclear risk of bias
[28, 29, 36, 38, 40–43] and eight were labelled high risk of
bias [30–35, 37, 39].
3.4 Results of Association Studies in the Complete
Populations
Results of the association studies are shown in Table 4.
3.4.1 Collagen
The most frequently studied gene was COL1A1. Conflict-
ing evidence was found for an association between TT and
Table 2 continued
Study Design Patients with ACL
rupture (n)
Controls
(n)
Gene Product Variant
Ste˛pien´-Słodkowska et al.
[43] 2015
Case–
control
138 183 COL5A1 Collagen rs13946
rs12722
ACAN aggrecan, BCN biglycan, COL12A1 collagen type XII, alpha 1, COL1A1 collagen type I, alpha 1, COL3A1 collagen type III, alpha 1,
COL5A1 collagen type V, alpha 1, COL6A1 collagen type VI, alpha 1, DCN decorin, ELN elastin, FBN2 fibrillin 2, FMOD fibromodulin, GDF5
growth differentiation factor 5, HIF1A hypoxia-inducible factor 1-alpha, KDR kinase insert domain receptor, LUM lumican, MMP1 matrix
metalloproteinase 1, MMP10 matrix metalloproteinase 10, MMP12 matrix metalloproteinase 12, MMP3 matrix metalloproteinase 3, NGFB nerve
growth factor beta, VEGFA vascular endothelial growth factor A
a Two different cohorts were analyzed in this study, as indicated by footnote ‘b’ or ‘c’
b South African population
c Polish population
Table 3 Risk-of-bias summary: review authors’ judgements of each risk-of-bias item for each included studya
Study Case
(1)
Control
(2)
Selection bias
(3)
Defined exposure
(4)
Determination
exposure (5)
Confounding
(6)
Overallb
Ficek et al. [28] 2013 ? ? ? ? ? ? ?
Ficek et al. [29] 2014 ? ? ? ? ? ? ?
Khoschnau et al. [30] 2008 ? ? ? ? ? - -
Khoury et al. [31] 2015 ? ? ? ? ? - -
Malila et al. [32] 2011 ? ? ? ? ? - -
Mannion et al. [33] 2014 ? ? ? ? ? - -
O’Connell et al. [34] 2015 ? ? ? ? ? - -
Posthumus et al. [35] 2009 ? ? ? ? ? - -
Posthumus et al. [36] 2009 ? ? ? ? ? ? ?
Posthumus et al. [37] 2010 ? ? ? ? ? - -
Posthumus et al. [38] 2012 ? ? ? ? ? ? ?
Rahim et al. [39] 2014 ? ? ? ? ? - -
Raleigh et al. [40] 2013 ? ? ? ? ? ? ?
Ste˛pien´-Słodkowska et al. [41]
2013
? ? ? ? ? ? ?
Ste˛pien´-Słodkowska et al. [42]
2015
? ? ? ? ? ? ?
Ste˛pien´-Słodkowska et al. [43]
2015
? ? ? ? ? ? ?
a Numbers 1–6 in the column headings correspond to the questions listed in Table 1; - indicates the risk of bias question was answered ‘no’, ?
indicates the risk of bias question was answered ‘yes’, ? indicates the risk of bias question could not be answered either ‘yes’ or ‘no’ and was
answered with a ‘doubtful’ or ‘unknown’
b - indicates a high risk of bias, ? indicates an unclear risk of bias
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Table 4 Results of genetic studies examining associations between genetic variants and anterior cruciate ligament rupture
Study Gene Protein Variant Genetic analysis OR (95% CI) p-Value Risk of bias
Ficek et al. [28] 2013 COL1A1 Collagen type I rs1800012 GG vs. GT ? TT Not shown [0.05 Unclear
GT vs. GG ? TT Not shown [0.05
TT vs. GG ? GT Not shown [0.05
rs1107946 GG vs. GT ? TT Not shown [0.05
GT vs. GG ? TT Not shown [0.05
TT vs. GT ? GG Not shown [0.05
Ficek et al. [29] 2014 COL12A1 Collagen type XII rs970547 GG vs. GA ? AA Not shown [0.05 Unclear
GA vs. GG ? AA Not shown [0.05
AA vs. GG ? GA Not shown [0.05
Khoschnau et al. [30]
2008
COL1A1 Collagen type I rs1800012 GG vs. GG 1 [0.05 High
GT vs. GG 1.19 (0.82–1.75) [0.05
TT vs. GG 0.12 (0.02–0.92) <0.05d
Khoury et al. [31]
2015
ELN Elastin rs2071307 GG vs. GA ? AA Not shown [0.05 High
GA vs. GG ? AA Not shown [0.05
AA vs. GG ? GA Not shown [0.05
FBN2 Fibrillin-2 rs331079 GG vs. GC ? CC Not shown [0.05
GC vs. GG ? CC Not shown [0.05
CC vs. GG ? GC Not shown [0.05
Malila et al. [32] 2011 MMP3 Matrix metalloproteinase
type 3
–1612 5A? vs. 5A- 1.39 (0.72–2.67) [0.05 High
5A- vs. 5A? 0.72 (0.37–1.38) [0.05
Mannion et al. [33]
2014
DCN Decorin rs516115 GG vs. GA ? AA 9.23 (1.17–73.01)e 0.015 High
GA vs. GG ? AA Not shown [0.05
AA vs. GG ? GA Not shown [0.05
rs13312816 AA vs. AT ? TT Not shown [0.05
AT vs. AA ? TT Not shown [0.05
TT vs. AA ? AT Not shown [0.05
ACAN Aggrecan rs2351491 CT vs. CC ? TT Not shown [0.05
CC vs. CT ? TT Not shown [0.05
TT vs. CT ? CC Not shown [0.05
rs1042631 TT vs. CT ? CC Not shown [0.05
CT vs. TT ? CC Not shown [0.05
CC vs. CT ? TT Not shown [0.05
rs1516797 TT vs. GT ? GG Not shown [0.05
GT vs. GG ? TT Not shown [0.05
GG vs. GT ? TT Not shown [0.05
BGN Biglycan rs1126499 CC vs. CT ? TT Not shown [0.05
CT vs. CC ? TT Not shown [0.05
TT vs. CC ? CT Not shown [0.05
rs1042103 GG vs. GA ? AA Not shown [0.05
GA vs. GG ? AA Not shown [0.05
AA vs. GG ? GA Not shown [0.05
FMOD Fibromodulin rs7543148 GG vs. GA ? AA Not shown [0.05
GA vs. GG ? AA Not shown [0.05
AA vs. GG ? GA Not shown [0.05
rs10800912 CC vs. CT ? TT Not shown [0.05
CT vs. CC ? CT Not shown [0.05
TT vs. CC ? CT Not shown [0.05
LUM Lumican rs2268578 TT vs. TC ? CC Not shown [0.05
TC vs. TT ? CC Not shown [0.05
CC vs. CT ? TT Not shown [0.05
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Table 4 continued
Study Gene Protein Variant Genetic analysis OR (95% CI) p-Value Risk of bias
O’Connell et al. [34]a
2015
COL3A1 Collagen type IIIb rs1800255 AA vs. GA ? GG Not shown [0.05 High
GA vs. GG ? AA Not shown [0.05
GG vs. AA ? GA Not shown [0.05
Collagen type IIIc AA vs. GA ? GG 3.8 (1.1–12.8) 0.036
GA vs. AA ? GG Not shown [0.05
GG vs. AA ? GA Not shown [0.05
Collagen type VIb rs35796750 TT vs. TC ? CC Not shown [0.05
TC vs. CC ? TC Not shown [0.05
CC vs. TT ? CT Not shown [0.05
Posthumus et al. [35]
2009
COL1A1 Collagen type I rs1800012 TT vs. GT ? GG 0.08 (\0.01–1.46) 0.031 High
GT vs. TT ? GG Not shown [0.05
GG vs. GG ? GT Not shown [0.05
Posthumus et al. [36]
2009
COL5A1 Collagen type V rs12722 TT vs. CT ? CC Not shown [0.05 Unclear
CT vs. TT ? CC Not shown [0.05
CC vs. TT ? CT Not shown [0.05
rs13946 TT vs. CT ? CC Not shown [0.05
CT vs. TT ? CC Not shown [0.05
CC vs. TT ? CT Not shown [0.05
Posthumus et al. [37]
2010
COL12A1 Collagen type XII rs970547 GG vs. GA ? AA Not shown [0.05 High
GA Vs. AA ? GG Not shown [0.05
AA VS. GG ? GA Not shown [0.05
rs240736 TT vs. CT ? CC Not shown [0.05
CT vs. TT ? CC Not shown [0.05
CC vs. TT ? CT Not shown [0.05
Posthumus et al. [38]
2012
MMP1 Matrix metalloproteinase type
1
rs1799750 CC vs. CT ? TT Not shown [0.05 Unclear
CT vs. CC ? TT Not shown [0.05
TT vs. CC ? CT Not shown [0.05
MMP3 Matrix metalloproteinase type
3
rs679620 1G1G vs.
1G2G ? 2G2G
Not shown [0.05
1G2G vs.
1G1G ? 2G2G
Not shown [0.05
2G2G vs.
1G1G ? 1G2G
Not shown [0.05
MMP10 Matrix metalloproteinase type
10
rs486055 GG vs. GA ? AA Not shown [0.05
GA vs. GG ? AA Not shown [0.05
AA vs. GG ? GA Not shown [0.05
MMP12 Matrix metalloproteinase type
12
rs2276109 AA vs. AG ? GG Not shown [0.05
AG vs. AA ? GG Not shown [0.05
GG vs. AA ? AG Not shown [0.05
Rahim et al. [39] 2014 VEGFA Vascular endothelial growth
factor A
rs699947 CC vs. CA ? AA Not shown [0.05 High
CA vs. CC ? AA Not shown [0.05
AA vs. CC ? CA Not shown [0.05
rs1570360 GG vs. GA ? AA Not shown [0.05
GA vs. GG ? AA 1.70 (1.16–2.50) 0.007
AA vs. GG ? GA Not shown [0.05
rs2010963 GG vs. GC ? CC Not shown [0.05
GC vs. GG ? CC Not shown [0.05
CC vs. GC ? GG Not shown [0.05
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GG genotype of the COL1A1 rs1800012 variant and ACL
rupture. Conflicting evidence was found for an association
between AA genotype of the COL3A1 rs1800255 variant
and ACL rupture. Limited evidence was found for no
association between COL5A1 rs12722, COL5A1 rs13946,
and COL12A1 rs970547 variants and ACL rupture. Insuf-
ficient evidence was found for no association between
COL1A1 rs1107946, COL6A1 rs35796750, and COL12A1
rs240736 variants and ACL rupture.
3.4.2 Proteoglycans
Insufficient evidence was found for an association between
GG (protective) genotype of the DCN rs516115 variant and
ACL rupture. Insufficient evidence was found for no
association between DCN rs13312816, ACAN rs2351491,
ACAN rs1042631, ACAN rs1516797, BGN rs1126499,
BGN rs1042103, FMOD rs7543148, FMOD rs10800912,
and LUM rs2268578 variants and ACL rupture.
Table 4 continued
Study Gene Protein Variant Genetic analysis OR (95% CI) p-Value Risk of bias
KDR Kinase insert
domain receptor
rs1870377 TT vs. TA ? AA Not shown [0.05
TA vs. TT ? AA Not shown [0.05
AA vs. TT ? AT Not shown [0.05
rs2071559 GG vs. GA ? AA Not shown [0.05
GA vs. GG ? AA Not shown [0.05
AA vs. GA ? GG Not shown [0.05
NGFB Nerve growth factor beta rs6678788 CC vs. CT ? TT Not shown [0.05
CT vs. GG ? TT Not shown [0.05
TT vs. GT ? CC Not shown [0.05
HIF1A Hypoxia-inducible
factor 1-alpha
rs11549465 CC vs. CT ? CC Not shown [0.05
CT vs. CC ? TT Not shown [0.05
TT vs. CT ? CC Not shown [0.05
Raleigh et al. [40]
2013
GDF5 Growth-differentiation
hormone factor
rs143383 TT vs. CT ? CC Not shown [0.05 Unclear
CT vs. TT ? CC Not shown [0.05
CC vs. TT ? CT Not shown [0.05
Ste˛pien´-Słodkowska
et al. [41] 2013
COL1A1 Collagen type I rs1800012 GG vs. GT ? TT Not shown 0.046 Unclear
GT vs. GG ? TT Not shown [0.05
TT vs. GT ? GG Not shown [0.05
Ste˛pien´-Słodkowska
et al. [42] 2015
COL3A1 Collagen type III rs1800255 GG vs. GA ? AA 0.78 (0.49–1.24) [0.05 Unclear
GA vs. GG ? AA Not shown [0.05
AA vs. GG ? GA 5.05 (1.62–15.78) 0.003
Ste˛pien´-Słodkowska
et al. [43] 2015
COL5A1 Collagen type V rs13946 CC vs. CT ? TT Not shown [0.05 Unclear
CT vs. CC ? TT Not shown [0.05
TT vs. CC ? CT Not shown [0.05
rs12722 CC vs. CT ? TT Not shown [0.05
CT vs. CC ? TT Not shown [0.05
TT vs. CC ? CT Not shown [0.05
Bold type indicates statistical significance (p\ 0.05)
ACAN aggrecan, ACL anterior cruciate ligament, BCN biglycan, COL12A1 collagen type XII, alpha 1, COL1A1 collagen type I, alpha 1, COL3A1 collagen
type III, alpha 1, COL5A1 collagen type V, alpha 1, COL6A1 collagen type VI, alpha 1, DCN decorin, ELN elastin, FBN2 fibrillin 2, FMOD fibromodulin,
GDF5 growth differentiation factor 5, HIF1A hypoxia-inducible factor 1-alpha, KDR kinase insert domain receptor, LUM lumican, MMP1 matrix
metalloproteinase 1, MMP10 matrix metalloproteinase 10, MMP12 matrix metalloproteinase 12, MMP3 matrix metalloproteinase 3, NGFB nerve growth
factor beta, OR odds ratio, VEGFA vascular endothelial growth factor A
a Two different cohorts were analysed in this study, as indicated by footnote ‘b’ or ‘c’
b South African group
c Polish group
d No exact p-value was reported
e This genotype was over-represented (OR = 9.23) in the control group compared with the ACL group, which is consistent with a protective effect in the
ACL group (OR = 1/9.23 = 0.11)
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3.4.3 Matrix Metalloproteinases
Insufficient evidence was found for no association between
MMP1 rs1799750, MMP3 rs679620, MMP3-1612, MMP10
rs486055, and MMP12 rs2276109 variants and ACL
rupture.
3.4.4 Angiogenesis-Associated Signaling Cascade
and Growth Differentiation Hormone Factor
Insufficient evidence was found for an association between
GA genotype (harmful) of the VEGFA rs1570360 variant
and ACL rupture. Insufficient evidence was found for no
association between VEFGA rs699947, VEFGA rs2010963,
KDR 1870377, KDR rs2071559, NGFB rs6678788, HIF1A
rs11549465, and GDF5 rs143383 variants and ACL
rupture.
3.4.5 Elastin and Fibrillin
Insufficient evidence was found for no association between
ELN rs2071307 variant and ACL rupture or for no asso-
ciation between FBN2 rs331079 variant and ACL rupture.
3.5 Stratified Analysis
In addition to the overall analyses, studies investigated
genetic variants in sex and/or (non-) contact stratified
analyses. However, because of the small sample sizes,
insufficient data were available to report sufficient evi-
dence regarding those analyses. Therefore, they were not
included in this review.
4 Discussion
In this systematic review, we summarized the current liter-
ature on genetic variants predicting the risk of ACL rupture.
We found conflicting evidence for the COL1A1 rs1800012
GG and TT genotype and COL3A1 rs1800255 AA genotype
and limited evidence for no association between COL5A1
rs13946,COL5A1 rs12722, andCOL12A1 rs970547 variants
and ACL rupture. We also found associations, albeit with
insufficient evidence, regarding the DCN rs516115 GG
genotype (protective) and VEGFA rs1570360 GA genotype
(harmful) and ACL rupture. Moreover, a large number of
genetic variants were found not to have an association.
However, those genetic variants were studied only once;
therefore, evidence for those DNA variants was also con-
sidered insufficient. We included 16 studies in this review,
with a total of 33 different genetic variants. Many studies
were found to have an unclear or high risk of bias and con-
founding. In addition, we identified large heterogeneity in
the genetic variants studied, outcome definition, and the
genetic contrast studied, which made it impossible to con-
duct a formal meta-analysis of these studies. Therefore, we
performed a best-evidence synthesis. Overall, we found
some potential genetic variants that could influence the risk
of ACL rupture. However, more data are needed to support a
clear association between genetic variants and ACL rupture.
Larger and more genetic studies are required to obtain a
better understanding of these possible associations.
John et al. [24] recently published a similar systematic
review. However, there are some notable differences
between the two studies. First, John et al. [24] presented the
results as a narrative review and concluded that, of the 20
genes examined, ten were positively associated with an
ACL rupture. Their review does not appear to fully justify
their finding that 50% (COL1A1, COL12A1, COL5A1,
COL3A1, MMP3, MMP12, and various ECM) of the genes
examined so far are positively associated with an ACL tear,
especially when mentioning contradictory results for some
specific genetic variants such as COL1A1 or COL3A1. The
current analysis presented the findings using a best-evi-
dence synthesis by van Tulder et al. [27]. A best-evidence
synthesis provides stronger evidence and takes a different
approach to presenting the results than does a simple nar-
rative summary. Consequently, the results and conclusions
of the current analysis concerning the associations between
genetic variants and ACL injury differ from and have
greater methodological power than those of John et al. [24].
Second, this review included two additional studies
[30, 40]. John et al. [24] excluded one of these [30] because
both the ACL and the posterior cruciate ligaments were
included and analysed together in one population group.
They also excluded a different study [40], likely because of
differences between our search strategies and because this
review searched more databases. Third, in contrast to John
et al. [24], we did not account for subgroups such as sex
and injury mechanism because of small sample sizes.
Fourth, this review concentrated on polymorphisms rather
than less well-studied haplotypes or alleles. Fifth, John
et al. [24] did not report the results of genetic variants for
which no association was found with ACL rupture. This
review represents a survey of all investigated genetic
variants and genotypes with their ORs and p-values, even if
no association was found at all. This approach was taken in
the interests of maximum transparency and clarity, allow-
ing readers and researchers to decide which genetic vari-
ants to investigate in the future, taking into account
confidence intervals and statistical significance data.
Variants of the investigated genes, displayed in Table 4,
are involved in the synthesis, strength, and homeostasis of
the ligament. COL1A1 encodes for collagen type I, which
provides mechanical strength to several tissues, including
ligaments [44]. COL3A1 encodes for collagen type III and
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is involved in collagen type I fibrillogenesis [45]. COL5A1
encodes collagen type V, which is engaged with collagen
type I in constructing heterotypic fibrils and also regulates
the diameter of those fibrils [46]. Collagen type XII,
encoded by COL12A1, is the largest member of the fibril-
associated collagens and regulates the organization and
mechanical properties of collagen fibril bundles [47].
Decorin, encoded by the DCN gene, belongs to the small
group of proteoglycans and is engaged in limiting the
diameter of collagen fibrils during fibrillogenesis [48].
VEGFA encodes vascular endothelial growth factor A, is a
regulator of angiogenesis, and increases the expression of
the matrix metalloproteinases [49]. The consequences of
those genetic variants are not exactly known. To date, a
limited number of the genetic variants involved in the
synthesis, strength, and homeostasis of the ligament have
been investigated. Moreover, most of those genetic variants
were only studied once. Only some genetic variants in or
near COL1A1 (4x), COL3A1 (3x), COL5A1 (2x), and
COL12A1 (2x) were studied in more than one independent
study/cohort.
Our included studies had some limitations. No limit
was set on minimum sample size to enable us to include
all possible studies because genetic studies require more
participants than most of our included studies had. Sample
size became very small when groups were stratified
according to sex or mechanism of injury and, therefore,
we did not report any stratified analyses. In total, 14
published studies used, partially or fully, the same pop-
ulation for cases and controls [28, 29, 31, 33–43], which
increased the risk of bias. Most likely, every gene variant
has its own potential, influencing the risk of an ACL
rupture. For example, the VEGFA rs1570360 and DCN
rs516115 variants were examined in nearly the same
population group, which was overrepresented in the ACL
rupture group [33, 39]. While both of these genetic vari-
ants could have increased the risk of ACL rupture, the
possibility remains that only one of them was the actual
risk contributor while the association of the other genetic
variant was modified (confounding or effect modification)
by the actual risk variant. Thus, another limitation is
possible: confounding by ethnicity (population stratifica-
tion). If the risk of an ACL rupture differs between dif-
ferent ethnicities but there is also a variation in the
statistical distribution of a genetic variant between ethnic
groups, the association between the ACL rupture and
genetic variant may be confounded by the ethnic back-
ground of the studied population [50].
The heterogeneity of several study aspects, such as
differences in population and type of genetic variants,
meant that a meta-analysis was not possible. Therefore, we
performed a best-evidence synthesis as an alternative. All
of our studies were case-controlled as it is nearly
impossible, and unnecessary, to conduct a randomized
controlled trial given the research question. However,
prospective cohort studies would provide stronger
evidence.
Another major issue remains the possible underlying
heterogenetic etiology in genetic studies, for example in
patients with osteoarthritis [51]. Therefore, future research
should also focus on evaluating larger samples and
resolving phenotype heterogeneity to facilitate more com-
prehensive study of the genetics of ACL rupture, for
example by investigating genetic variants in established
genome-wide studies conducted to assess other factors such
as osteoarthritis [51–54].
In the risk-of-bias assessment, eight studies were con-
sidered at high risk of bias. Eight studies were labelled at
unclear risk of bias, which exemplifies the quality of the
research and the conclusions that can be distilled.
Research has already been conducted for various genes
involved in production, strength, or homeostasis of the
ACL. However, as mentioned, larger and more genetic
studies are required to provide a better understanding of the
possible associations with ACL rupture. Every genetic
variant examined should be re-examined to obtain a better
understanding of the influence of these genes. Furthermore,
research is encouraged for collagen and matrix metallo-
proteinase genes other than those already studied [55, 56].
Tendons and ligaments largely share the same components
and both belong to the soft tissues. A systematic review by
Claessen et al. [57] indicated no association between the
COL1A1 rs1800012 variant and Achilles tendon ruptures,
which does not clarify whether ACL and Achilles tendon
ruptures might share the same genetic risk factors. More
variants found in tendon ruptures, such as the TIMP gene,
should also be investigated in relation to ACL ruptures
[57]. This also applies to genetic variants found in
osteoarthritis, since ACL rupture is a major risk factor for
osteoarthritis [52, 53].
Some studies addressed the interaction between two
gene variants on one chromosome, called haplotypes,
which were found to modify the risk of an ACL rupture
[28, 33, 34, 38, 39]. If genetic variants were not found to
influence the risk, an association was still found due to the
haplotype of those two gene variants. More research would
be needed to clarify the exact role of haplotypes.
The examination of ACL rupture genetics is valuable,
since knowledge of the genetic variants involved could
contribute to an understanding of the etiology and risk
factors in ACL tears. In addition, genetic variants could
help in screening and prevention. Each person has a unique
genetic profile. Some studies already suggest using genetic
profiles to enhance athletic performance [58, 59]. Taking
appropriate preventive measures might decrease the risk of
an ACL rupture, as well as its costs [60, 61].
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Screening for genetic variants could be implemented in
different scenarios. Professional sports organizations might
take appropriate measures regarding players at high risk of
an ACL rupture. High-risk players could decide at a young
age not to start a career in high-risk sports. Furthermore,
screening could be implemented in families with an active
lifestyle if a first-degree relative has a history of an ACL
rupture. However, in reality, screening for risk of ACL
rupture would be a complex task. It should be noted that
none of the genetic variants solely influence the risk and
thus could not be used as a diagnostic tool in isolation. As
previously stated, an ACL rupture is determined by various
intrinsic and extrinsic factors in which each factor con-
tributes a small amount to the risk. Therefore, multifacto-
rial and comprehensive models are designed to predict the
risk of ACL rupture [62]. In future, when an association
with genetics is found, genetic risk factors might be
included in the current multifactorial models predicting the
risk of ACL rupture [63]. Appropriate screening and pre-
vention programs might be implemented based on those
models. Individuals understand, and are interested in, the
benefits of genomic testing in psychological and medical
terms [64]. Unfortunately, genetic testing remains a source
of moral and ethical controversy [64, 65].
5 Conclusion
More evidence is needed to draw significant conclusions
regarding the association between genetic variants and
ACL rupture. We did find some genetic variants that
potentially contribute. Conflicting evidence was found for
COL1A1 rs1800012 and COL3A1 rs1800255, whereas
limited evidence was found for no association with
COL5A1 rs13946, COL5A1 rs12722, and COL12A1
rs970547. Finally, we found insufficient evidence for an
association between ACL rupture and DCN rs516115 GG
genotype (protective) or VEGFA rs1570360 GA genotype
(harmful). The genetic variants included in this systematic
review account for only a small number of the genes
involved in the biology of the ligament. ACL rupture has a
high incidence and incurs extreme consequences. There-
fore, more high-quality and homogenous data are needed to
provide a better understanding of the etiology, which in
future might improve screening and prevention programs.
Research should primarily focus on the components and
homeostasis of the ligament. These future genetic investi-
gations should be performed in large (collaborative) gen-
ome-wide association studies with large sample sizes and
phenotype homogeneity to explore for more potential
genetic variants. However, and more importantly, future
research should focus on (large) prospective studies so that
clinically significant conclusions can be drawn.
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